🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Tamoxifen, Letrozole, Anastrozole or Exemestane

Found 78 matching trials

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

PHASE3

POLAR is a phase III clinical trial, which will test the safety and efficac...

Status

Active Not Recruiting

Location

Medizinische Universität Graz (MUG)

Start Date

2019-08-27

Trial ID

NCT03820830

Treatments Being Tested

Palbociclib 125mg Standard endocrine therapy

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

N/A

Although randomized controlled trials (RCTs) provide evidence of efficacy, ...

Status

Completed

Location

Novartis Investigative Site

Start Date

2016-03-15

Trial ID

NCT02753686

Treatments Being Tested

Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

PHASE3

The objective of this trial, DBCG R25, will be to evaluate the effect of tr...

Status

Withdrawn

Location

Multiple Locations

Start Date

2026-01-01

Trial ID

NCT06585969

Treatments Being Tested

Trastuzumab deruxtecan (T-DXd)Ribociclib with ET Abemaciclib with ET

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors

PHASE2

The purpose of this neoadjuvant trial is to evaluate efficacy and toxicity ...

Status

Active Not Recruiting

Location

Department of Oncology, Karolinska University Hospital

Start Date

2015-10

Trial ID

NCT02592083

Treatments Being Tested

Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin Palbociclib

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

PHASE2

The majority of patients (pts) with breast cancer have hormone receptor pos...

Status

Active Not Recruiting

Location

University of Miami

Start Date

2023-06-12

Trial ID

NCT05826964

Treatments Being Tested

AI+CDK4/6i SERD+CDK4/6i mTOR inhibitor + AI mTOR inhibitor + SERD mTOR inhibitor + Selective estrogen receptor modulator PI3K inhibitor + SERD PI3K inhibitor + AI Chemotherapy Oral SERD PARPi AKT inhibitor Step 3 Arm 2

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

PHASE2

This was an open label, multi-center protocol for U.S. patients enrolled in...

Status

Completed

Location

Arizona Oncology Associates PC- HAL

Start Date

2017-06-20

Trial ID

NCT03078751

Treatments Being Tested

Ribociclib Adjuvant endocrine therapy Placebo

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

PHASE3

This Phase III Trial evaluates whether breast conservation surgery and endo...

Status

Recruiting

Location

University of Alabama at Birmingham Cancer Center

Start Date

2021-06-23

Trial ID

NCT04852887

Treatments Being Tested

Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

PHASE1

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study e...

Status

Recruiting

Location

Ellison Clinic at Saint John's

Start Date

2023-04-17

Trial ID

NCT05768139

Treatments Being Tested

STX-478 Fulvestrant Ribociclib Palbociclib Letrozole Anastrozole Exemestane Tamoxifen Abemaciclib Imlunestrant Metformin

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

PHASE1

This phase Ib trials studies the side effects and how well talimogene laher...

Status

Completed

Location

University of California, San Francisco

Start Date

2020-02-05

Trial ID

NCT03554044

Treatments Being Tested

Anastrozole Exemestane Fulvestrant Letrozole Paclitaxel Talimogene Laherparepvec Tamoxifen Nab paclitaxel Gemcitabine Carboplatin

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

PHASE2

This research study is evaluating a drug called Palbociclib in combination ...

Status

Completed

Location

University of California, San Francisco

Start Date

2014-01

Trial ID

NCT02040857

Treatments Being Tested

Palbociclib Aromatase Inhibitor

Previous Next